COVID-19, Rabies
Conditions
Brief summary
Evaluation of immunogenicity and safety of inactivated COVID-19 vaccine (BBIBP-Cov) coadministered with rabies vaccine.
Detailed description
The participants aged ≥18 who had received two doses of inactivated COVID-19 vaccine were recruited and randomly assigned to one of three study groups: Co-Ad group, COVID-19 vaccine group and Rabies vaccine group. The participants in Co-Ad group and COVID-19 vaccine group received a booster dose of inactivated COVID-19 vaccine.The participants in Co-Ad group and Rabies vaccine group received three doses of rabies vaccine for pre-exposure immunization. The participants in Co-Ad group received the first dose of rabies vaccine (Day 0) and the inactivated COVID-19 vaccine simultaneously. Any local or systemic adverse events after vaccination will be recorded.
Interventions
BIOLOGICALcoadministration
the coadministration of an inactivated COVID-19 vaccine (BBIBP-CorV) and rabies vaccine
BIOLOGICALCOVID-19 vaccine
received one dose of inactivated COVID-19 vaccine (BBIBP-CorV)
BIOLOGICALrabies vaccine
received three dose of rabies vaccine
Sponsors
Guizhou Center for Disease Control and Prevention
Shaanxi Provincial Center for Disease Control and Prevention
Beijing Institute of Biological Products Co Ltd.
Changchun Institute of Biological Products Co., Ltd.
China National Biotec Group Company Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participants aged ≥18. * Have the ability to understand the study procedures, voluntarily sign informed consent. * Be able and willing to complete the entire study plan during the study follow-up period. * Participants have not received any rabies vaccine. * Participants have received 2 doses of inactivated COVID-19 vaccine for 6-12 months. * The time interval between the last vaccination is ≥14 days. * Body temperature \< 37.3 °C confirmed by clinical examination before enrollment .
Exclusion criteria
for the first dose: * Participants who have received the third dose of COVID-19 vaccine. * Participants who have previously been infected with COVID-19 or who have tested positive for SARS-CoV-2. * Having a history or family history of convulsions, epilepsy, encephalopathy and psychosis. * Being allergic to any component of vaccines and a history of severe allergic reactions to any vaccine. * Participants are suffering from immunodeficiency, receiving immunosuppressant therapy (oral steroid hormones) during treatment for malignancy, or having low immunity due to HIV within 14 days before enrollment, or having congenital immune disorders in close family members. * Injection of non-specific immunoglobulin within 1 month before enrollment. * Participants are suffering from acute febrile diseases and infectious diseases, or have used anti-inflammatory/antiviral/antipyretic/antiallergic drugs within 3 days before enrollment. * A history of clearly diagnosed thrombocytopenia or other clotting disorders that may contraindicate subcutaneous injection. * Participants with severe chronic diseases or acute episodes of chronic diseases, hypertension or diabetes that cannot be controlled by drugs. * Participants with infectious, suppurative and allergic skin diseases. * Pregnant and lactating women. * Other Participants whose physical conditions, as determined by the investigator, are not suitable for inclusion in clinical studies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutralizing antibody GMI against rabies virus | 14 days after the 3th dose (Day 42) | Neutralizing antibody GMI against rabies virus after 3th dose |
| Neutralizing antibody GMC against rabies virus | 14 days after the 3th dose (Day 42) | Neutralizing antibody GMC against rabies virus after 3th dose |
| Neutralizing antibody GMI against SARS-CoV-2 | 28 days after vaccination (Day 28) | Neutralizing antibody GMI against SARS-CoV-2 after vaccination |
| Seroconversion rate against SARS-CoV-2 | 28 days after vaccination (Day 28) | The rate of seroconversion against SARS-CoV-2 |
| Seroconversion rate against rabies virus | 14 days after the 3th dose (Day 42) | The rate of seroconversion against rabies virus |
| Neutralizing antibody GMT against SARS-CoV-2 | 28 days after vaccination (Day 28) | Neutralizing antibody GMT against SARS-CoV-2 after vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serious adverse event rate | 0-6 months | Report and analyse serious adverse events |
| Adverse events rate | 0-7 days or 0-28 days following vaccinations | Analyse the incidence of adverse events following vaccination, both solicited and unsolicited |
Countries
China
Contacts
Primary ContactRuizhi Zhang
Outcome results
None listed